Cell MedX Corp. – ‘10-Q’ for 8/31/17 – ‘EXCEL’

On:  Monday, 10/16/17, at 5:32pm ET   ·   As of:  10/17/17   ·   For:  8/31/17   ·   Accession #:  1393905-17-315   ·   File #:  0-54500

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    286K 
 6: EX-10.55    Loan Agreement and Note Payable Dated July 12,      HTML     25K 
                2017, Among Cell Medx Corp., and Richard N. Jeffs                
 7: EX-10.56    Stock Option Agreement Dated August 24, 2017 Among  HTML     65K 
                Cell Medx Corp. and Yanika Silina                                
 8: EX-10.57    Stock Option Agreement Dated August 24, 2017 Among  HTML     65K 
                Cell Medx Corp. and Da Costa Management Corp.                    
 9: EX-10.58    Stock Option Agreement Dated August 24, 2017 Among  HTML     65K 
                Cell Medx Corp. and John Giovanni Di Cicco                       
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
16: R1          Document and Entity Information                     HTML     45K 
17: R2          Consolidated Balance Sheets                         HTML     76K 
18: R3          Balance Sheets (Parenthetical)                      HTML     28K 
19: R4          Consolidated Statements of Operations               HTML     64K 
20: R5          Consolidated Statements of Stockholders' Equity     HTML     68K 
                (Deficit)                                                        
21: R6          Consolidated Statements of Stockholders' Equity     HTML     21K 
                (Parenthetical)                                                  
22: R7          Consolidated Statements of Cash Flows               HTML     85K 
23: R8          Organization and Nature of Operations               HTML     26K 
24: R9          Related Party Transactions, Disclosure              HTML     46K 
25: R10         Equipment, Disclosure                               HTML     28K 
26: R11         Inventory Disclosure                                HTML     22K 
27: R12         Unearned Revenue Disclosure                         HTML     22K 
28: R13         Notes and Advances Payable, Disclosure              HTML     57K 
29: R14         Share Capital, Disclosure                           HTML     59K 
30: R15         Subsequent Events Disclosure                        HTML     23K 
31: R16         Organization and Nature of Operations: Unaudited    HTML     23K 
                Interim Financial Statements (Policies)                          
32: R17         Organization and Nature of Operations: Going        HTML     23K 
                Concern (Policies)                                               
33: R18         Related Party Transactions, Disclosure: Schedule    HTML     30K 
                of Amounts Due to Related Parties (Tables)                       
34: R19         Related Party Transactions, Disclosure: Schedule    HTML     35K 
                of Transactions with Related Parties (Tables)                    
35: R20         Equipment, Disclosure: Amortization Schedule for    HTML     28K 
                Equipment (Tables)                                               
36: R21         Notes and Advances Payable, Disclosure: Schedule    HTML     44K 
                of Short-term Loans and Advances Outstanding                     
                (Tables)                                                         
37: R22         Notes and Advances Payable, Disclosure: Fair        HTML     24K 
                values assumptions of the warrants - Term Loan                   
                Agreement (Tables)                                               
38: R23         Share Capital, Disclosure: Black-Scholes Option     HTML     24K 
                pricing valuation - Stock Options granted August                 
                24, 2017 (Tables)                                                
39: R24         Share Capital, Disclosure: Schedule of Stock        HTML     36K 
                Option Activity (Tables)                                         
40: R25         Share Capital, Disclosure: Schedule of Stock        HTML     29K 
                Options Outstanding (Tables)                                     
41: R26         Share Capital, Disclosure: Schedule of Warrant      HTML     26K 
                Activity (Tables)                                                
42: R27         Share Capital, Disclosure: Schedule of Warrant      HTML     27K 
                Details (Tables)                                                 
43: R28         Organization and Nature of Operations: Going        HTML     22K 
                Concern (Details)                                                
44: R29         Related Party Transactions, Disclosure: Schedule    HTML     30K 
                of Amounts Due to Related Parties (Details)                      
45: R30         Related Party Transactions, Disclosure: Schedule    HTML     37K 
                of Transactions with Related Parties (Details)                   
46: R31         Equipment, Disclosure: Amortization Schedule for    HTML     28K 
                Equipment (Details)                                              
47: R32         Inventory Disclosure (Details)                      HTML     24K 
48: R33         Unearned Revenue Disclosure (Details)               HTML     24K 
49: R34         Notes and Advances Payable, Disclosure: Schedule    HTML     38K 
                of Short-term Loans and Advances Outstanding                     
                (Details)                                                        
50: R35         Notes and Advances Payable, Disclosure (Details)    HTML     42K 
51: R36         Share Capital, Disclosure (Details)                 HTML     21K 
52: R37         Share Capital, Disclosure: Schedule of Stock        HTML     32K 
                Option Activity (Details)                                        
53: R38         Share Capital, Disclosure: Schedule of Stock        HTML     33K 
                Options Outstanding (Details)                                    
54: R39         Share Capital, Disclosure: Schedule of Warrant      HTML     23K 
                Activity (Details)                                               
55: R40         Share Capital, Disclosure: Schedule of Warrant      HTML     22K 
                Details (Details)                                                
56: R41         Subsequent Events Disclosure (Details)              HTML     27K 
58: XML         IDEA XML File -- Filing Summary                      XML     98K 
57: EXCEL       IDEA Workbook of Financial Reports                  XLSX     39K 
10: EX-101.INS  XBRL Instance -- cmxc-20170831                       XML    507K 
12: EX-101.CAL  XBRL Calculations -- cmxc-20170831_cal               XML     46K 
13: EX-101.DEF  XBRL Definitions -- cmxc-20170831_def                XML    196K 
14: EX-101.LAB  XBRL Labels -- cmxc-20170831_lab                     XML    390K 
15: EX-101.PRE  XBRL Presentations -- cmxc-20170831_pre              XML    355K 
11: EX-101.SCH  XBRL Schema -- cmxc-20170831                         XSD     98K 
59: ZIP         XBRL Zipped Folder -- 0001393905-17-000315-xbrl      Zip     49K 

‘EXCEL’   —   IDEA Workbook of Financial Reports

This is an IDEA Workbook.

Download this Microsoft® Excel® .xlsx workbook

19 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/16/24  Cell MedX Corp.                   10-Q       11/30/23   46:2.3M                                   Empire Stock Transf… Inc
10/16/23  Cell MedX Corp.                   10-Q        8/31/23   42:1.9M                                   Empire Stock Transf… Inc
 9/01/23  Cell MedX Corp.                   10-K        5/31/23   73:3.2M                                   Empire Stock Transf… Inc
 6/29/23  Cell MedX Corp.                   10-Q        2/28/23   53:2.5M                                   Empire Stock Transf… Inc
 5/19/23  Cell MedX Corp.                   10-Q       11/30/22   53:2.4M                                   Empire Stock Transf… Inc
 4/19/23  Cell MedX Corp.                   10-Q        8/31/22   51:2.2M                                   Empire Stock Transf… Inc
 4/07/23  Cell MedX Corp.                   10-K        5/31/22   90:3.6M                                   Empire Stock Transf… Inc
 4/11/22  Cell MedX Corp.                   10-Q        2/28/22   56:2.5M                                   Empire Stock Transf… Inc
 1/12/22  Cell MedX Corp.                   10-Q       11/30/21   54:2.4M                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   424B3                  1:365K                                   Empire Stock Transf… Inc
10/14/21  Cell MedX Corp.                   10-Q        8/31/21   50:2.2M                                   Empire Stock Transf… Inc
10/12/21  Cell MedX Corp.                   424B3                  1:705K                                   Empire Stock Transf… Inc
 8/30/21  Cell MedX Corp.                   10-K        5/31/21   83:3.7M                                   Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   424B3                  1:501K                                   Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   10-Q        2/28/21   56:2.8M                                   Empire Stock Transf… Inc
 3/04/21  Cell MedX Corp.                   S-1                   78:3.8M                                   Empire Stock Transf… Inc
 1/14/21  Cell MedX Corp.                   10-Q       11/30/20   53:2M                                     Empire Stock Transf… Inc
10/15/20  Cell MedX Corp.                   10-Q        8/31/20   51:1.9M                                   Empire Stock Transf… Inc
 9/15/20  Cell MedX Corp.                   10-K        5/31/20   84:2.9M                                   Empire Stock Transf… Inc